Seattle Genetics to Present at the JPMorgan Annual Healthcare Conference
- Category: Antibodies
- Published on Tuesday, 09 January 2007 02:00
- Hits: 6067
BOTHELL, WA, USA | Jan 08, 2007 | Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 25th Annual JPMorgan Healthcare Conference on Thursday, January 11, 2007, at 12:30 p.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. Dr. Siegall's presentation will provide an update on the company's programs, including the recently announced exclusive global licensing agreement with Genentech for the development and commercialization of SGN-40.
A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the "news and investor information" section.
About Seattle Genetics
Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including non-Hodgkin's lymphoma, multiple myeloma, acute myeloid leukemia and Hodgkin's disease. The company has also developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition to its worldwide development agreement for SGN-40 with Genentech, Seattle Genetics currently has license agreements for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune. More information can be found at http://www.seattlegenetics.com.
CONTACT: Seattle Genetics
Peggy Pinkston, Corporate Communications
SOURCE: Seattle Genetics, Inc.